Reply to: “Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?” and “External validation of noninvasive predictors of hepatocellular carcinoma in patients with HCV advanced chronic liver disease after ora l antivirals”

We thank Nabatchikova et  al.1 and Shiba et al.2 for their interest and comments on our work.3 First, we would like to explain that the main reason for predicting an event (hepatocellular carcinoma [HCC] in this case) is to guide future action (for example HCC screening). In our study, our initial aim was to identify a su bpopulation of patients with compensated advanced chronic liver disease (cACLD), in whom HCV had been cured, who could avoid HCC surveillance; unfortunately, we failed. All HCV-cured patients with cACLD need continued HCC screening.

Source: Journal of Hepatology - May 31, 2020 Category: Gastroenterology Authors: Joan Genesc à Tags: Letter to the Editor Source Type: research